Is AstraZeneca on track to meet its $80B revenue target?
LONDON — In 2024, AstraZeneca’s CEO Pascal Soriot set a new goal: for the company to pull in $80 billion in annual sales by 2030. At that time, this target looked ambitious. But ...
View ArticleNIH stops low-dose Xarelto arm of large stroke study due to safety concerns
The National Institutes of Health has halted an arm of a large trial investigating whether J&J and Bayer's blood thinner Xarelto is superior to the standard of care for lowering the rate of stroke...
View ArticleAbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
A US appeals court upheld a Louisiana law regulating how 340B-discounted drugs are distributed to patients, dealing another setback to the pharma industry as drugmakers continue fighting state...
View ArticleILiAD raises $115M round to advance whooping cough vaccine
It isn’t all doom and gloom in the vaccine industry. ILiAD Biotechnologies announced a $115 million oversubscribed Series B on Tuesday — enough money to start accruing pivotal Phase 3 data of ...
View ArticleIsomorphic claims major advance with new AI drug design engine
Nearly two years ago, Isomorphic Labs dropped AlphaFold 3, the latest generation of its Nobel Prize-winning, structure-predicting AI model. Now the company claims it has another major advance on its...
View ArticleModerna accuses FDA of shifting standard as agency refuses flu shot review
The FDA said it won't review Moderna’s flu vaccine application, a surprise decision that the company is describing as a shifting of the standards for its pivotal trial well after it thought it had...
View ArticleUpstream Bio's stock slides on Phase 2 severe asthma data for verekitug
Upstream Bio on Wednesday said its TSLP-targeting drug met its goal in a mid-stage trial in severe asthma, which is a step forward in its bid to challenge Dupixent and Tezspire down the line. ...
View ArticleSanofi invests in China startup GluBio in developing molecular glue for...
A small startup based in San Diego and Shanghai believes it has figured out how to boost hemoglobin levels with a pill, potentially offering a cheaper and simpler alternative to expensive and onerous...
View ArticlePost-Hoc Live: Is biotech’s relationship with the FDA at a breaking point?
For years, the wisdom in biopharma was that you don’t pick a fight with the FDA in public. But that’s changed over the last year, as biopharma companies have become increasingly critical of what they...
View ArticleOscar Health expects explosive growth for 2026, but it comes with a risk
Oscar Health added more than a million new members to its insurance rolls during the recent open enrollment period, fueling what it projects to be massive growth for 2026. When reporting 2025 results...
View ArticleHow a closet full of EKG machines illustrates pharma’s clinical trial cost...
When Jake Van Naarden visits a hospital running clinical trials, he runs into an odd sight. Van Naarden, the head of Eli Lilly's oncology unit, opens a supply closet and sees more than a dozen ...
View ArticleGubra forms venture unit; Galecto's $275M offering
Plus, news about THX Pharma and Biocodex: 🏗️ Gubra's venture unit: The Danish biotech and CRO operator, which is partnered with AbbVie and Boehringer Ingelheim, has created Gubra Ventures to build ...
View ArticleMadrigal pads MASH pipeline with six siRNAs from China's Ribo
Madrigal Pharmaceuticals is on a mission to become a generational, independent player in the MASH field with its third deal in eight months. The first FDA-approved medicine for the fatty liver disease,...
View ArticleAfter CEO departs, CSL details profit crash, $1.1B impairment costs
One day after bumping out CEO Paul McKenzie, Australia’s CSL revealed what he left behind: declining profit and a $1.1 billion hole due to lower US vaccine demand and increased generic competition. CSL
View ArticlePrasad overruled vaccine review team, office director on Moderna flu shot
Vinay Prasad, director of the FDA's office of biologics and vaccines, overruled both the vaccine review team and the head of the FDA's vaccine team as part of the ...
View ArticleFormer AstraZeneca senior staff charged with illegal trade in China
Chinese prosecutors have charged two of AstraZeneca’s former senior employees with illegal trade, unlawful collection of personal information, and medical insurance fraud, the company said this week....
View ArticleFDA may consider Moderna's flu vaccine in a narrower group
The FDA may be more willing to look at Moderna’s mRNA-based flu vaccine if the company re-filed it for a narrower group of older adults, a senior agency official told reporters in a call Wednesday ...
View ArticleHinge Health is looking to build AI tools for mental health support
Hinge Health is building an AI-powered mental health platform alongside its virtual physical therapy services, according to job listings Endpoints News viewed. Among the listings, the company is...
View ArticleEuropean VCs form coalition to get more support for biotech investing
Some of Europe's largest biotech investors are banding together in an effort to drive more private and public capital toward homegrown medicines and startups. Novo Holdings, Forbion, Sofinnova...
View Article